pharmaphorum

MARCH 23, 2022

Four out of five biopharma companies think that the market opportunity for connected health products exceeds their traditional drug business, but adoption remains low, with only 20% of use cases at present going beyond proof of concept. That’s one of the conclusions of a new study by Capgemini, which suggests that the number of approved connected health offerings – digital health products and services including wearables, digital therapeutics and software-as-a-medical-device (SaMD) – will

115

115

PharmD Live

MARCH 23, 2022

If you’ve implemented chronic care management (CCM) or remote physiologic monitoring (RPM, a.k.a. remote patient monitoring) in your practice, you know that they generate new streams of revenue while allocating more time to take better care of your patients—with potentially life-saving results. In fact, Medicare is so confident that these programs will pay off that it has dramatically increased CCM overall reimbursement rates for 2022.

52

52

pharmaphorum

MARCH 23, 2022

Whether you’re a large pharma company or a small, emerging one, communication is key. Success or failure hinges on communicating the advantages of your offerings to both prescribing providers and patients. Join us on Tuesday 12 th April at 13:00 BST / 14:00 CET / 8:00 am EDT as panelists lay out how a better approach to communication can lead to improved patient outcomes, preventing drop-off rates, better predicting product forecasts, increasing script volume, integrating localised digital strat

Communication 105

Communication Pharmaceutical Companies Pharmaceutical Companies 105

Pharma Marketing Network

MARCH 23, 2022

REGISTER HERE. Join PMN and industry marketing experts on April 28th at 12PM EST , to learn more about how to elevate your patient engagement marketing. Panels include: Effective Use of Data in DTC Marketing. There is no question that data is the path to better understanding your audience, but what data points are most important? What’s useful, and what’s misleading?

52

52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

MARCH 23, 2022

It’s only been two weeks since Pfizer closed its $6.7 billion takeover of Arena Pharmaceuticals, and it already has the positive data it was hoping for with etrasimod, the main asset in the deal. In its first phase 3 readout, oral S1P receptor modulator etrasimod met its objectives in patients with moderately-to-severely active ulcerative colitis, who had previously failed or were intolerant to at least one prior conventional, biological or JAK inhibitor therapy.

98

98

Med Ed 101

MARCH 23, 2022

As a geriatric pharmacist, I understand how difficult it can be to manage polypharmacy and pain management. I had the honor of being invited onto the Pain Pod. This podcast is put together by Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS. We addressed many different aspects of polypharmacy and pain management in our 40+ minute […]. The post Polypharmacy and Pain Management – Podcast Special!

40

40

Pharma Times

MARCH 23, 2022

Digital-first patient care is a priority as the companies join forces to improve patients' lives

Patient Care 44

Patient Care 44

pharmaphorum

MARCH 23, 2022

With initiatives like The 100,000 Genome Project, the UK has led the world on genomic research. In a bid to maintain that position, the governments of all four UK nations have now pledged their support for the sectors’ industry players. Representatives from industry associations and the governments and NHS in all four UK nations will meet to discuss the future of the country’s genomics sector.

72

72

Pharma Times

MARCH 23, 2022

Groups including those aged over 75-years-old, care home residents and the immunocompromised will be entitled to a fourth jab

Vaccines 36

Vaccines 36

pharmaphorum

MARCH 23, 2022

In this webinar, speakers from the NIHR and Roche will discuss what data is available to life science companies and CROs, how it’s currently being used for research planning and placement, and what more could be done with that data. They’ll also look at what culture and process changes will be required to make sure this data can be readily translated into insights to improve commercial research delivery.

52

52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

pharmaphorum

MARCH 23, 2022

Argenx only recently scored FDA approval for its intravenous anti-neonatal FC receptor (FcRn) antibody Vyvgart for generalised myasthenia gravis (gMG), but is already looking to defend its franchise with a new subcutaneous version of the drug. Vyvgart (efgartigimod alfa) became the first drug in the FcRn class to be approved by the FDA last December, and despite a $225,000 annual price tag is predicted to make relatively modest sales in its IV version, which will compete with other IV gMG drugs

FDA 52

FDA 52

pharmaphorum

MARCH 23, 2022

The world is re-balancing but the pharmaceutical industry’s engagement with HCPs has been tilted on its axis sending time-honoured engagement tactics into disarray. Face-to-face opportunities are drastically restricted and the focus is now laser-sharp on making every second of any contact count. It is a radical new world and new skills are needed to augment existing strategies.

Communication 52

Communication Hospitals 52

pharmaphorum

MARCH 23, 2022

Israeli startup Nucleai has raised $33 million in a second-round financing that will be used to further its work on using artificial intelligence and spatial biology to find biomarkers that can predict which patients will respond to cancer treatments. The five-year-old company uses machine vision and learning technology originally developed for military applications to predict how tumours will progress, and help to select the most effective treatment for the cancer.

Immunization 52

Immunization 52

pharmaphorum

MARCH 23, 2022

The US Senate will vote in the coming weeks on whether to introduce a $35 cap on the monthly cost of insulin to patients that was endorsed by President Joe Biden in his 2022 State of the Union address. Senate Majority Leader Chuck Schumer said yesterday that a vote on legislation which would introduce the cap – already backed in a House of Representatives vote last November – would take place this spring after the April recess.

Insurance 75

Insurance FDA 75

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software